JP5590621B2 - 炎症性障害の処置を処置するためのアネキシンおよびその使用 - Google Patents

炎症性障害の処置を処置するためのアネキシンおよびその使用

Info

Publication number
JP5590621B2
JP5590621B2 JP2011531312A JP2011531312A JP5590621B2 JP 5590621 B2 JP5590621 B2 JP 5590621B2 JP 2011531312 A JP2011531312 A JP 2011531312A JP 2011531312 A JP2011531312 A JP 2011531312A JP 5590621 B2 JP5590621 B2 JP 5590621B2
Authority
JP
Japan
Prior art keywords
annexin
composition
sepsis
variant
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011531312A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012505837A5 (enExample
JP2012505837A (ja
Inventor
チンピン フェン，
シャンル リ，
ポール アーノルド，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
London Health Sciences Centre Research Inc
Original Assignee
London Health Sciences Centre Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42106169&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5590621(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by London Health Sciences Centre Research Inc filed Critical London Health Sciences Centre Research Inc
Publication of JP2012505837A publication Critical patent/JP2012505837A/ja
Publication of JP2012505837A5 publication Critical patent/JP2012505837A5/ja
Application granted granted Critical
Publication of JP5590621B2 publication Critical patent/JP5590621B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011531312A 2008-10-17 2009-10-16 炎症性障害の処置を処置するためのアネキシンおよびその使用 Active JP5590621B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10639008P 2008-10-17 2008-10-17
US61/106,390 2008-10-17
PCT/CA2009/001469 WO2010043045A1 (en) 2008-10-17 2009-10-16 Annexin and its use to treat inflammatory disorders

Publications (3)

Publication Number Publication Date
JP2012505837A JP2012505837A (ja) 2012-03-08
JP2012505837A5 JP2012505837A5 (enExample) 2012-12-06
JP5590621B2 true JP5590621B2 (ja) 2014-09-17

Family

ID=42106169

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011531312A Active JP5590621B2 (ja) 2008-10-17 2009-10-16 炎症性障害の処置を処置するためのアネキシンおよびその使用

Country Status (6)

Country Link
US (1) US9192649B2 (enExample)
EP (1) EP2349321B1 (enExample)
JP (1) JP5590621B2 (enExample)
CN (1) CN102256617B (enExample)
CA (1) CA2740557C (enExample)
WO (1) WO2010043045A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5590621B2 (ja) 2008-10-17 2014-09-17 ロンドン ヘルス サイエンシーズ センター リサーチ インコーポレイテッド 炎症性障害の処置を処置するためのアネキシンおよびその使用
EP2380023A2 (en) 2008-12-19 2011-10-26 Medirista Biotechnologies AB Oxidized cardiolipin as a novel pro-inflammatory factor
WO2011160845A2 (en) 2010-06-24 2011-12-29 Medirista Biotechnologies Ab Oxidized phospholipids and lipoproteins, and antibodies thereto, as biomarkers of inflammatory conditions and methods of treatment
CN102690345B (zh) * 2011-03-24 2014-03-19 江苏靶标生物医药研究所有限公司 人膜联蛋白v变体及其表达、制备和应用
PL2720707T3 (pl) * 2011-06-15 2019-06-28 Resother Pharma Aps Przeciwzapalne produkty farmaceutyczne
WO2013124327A1 (en) 2012-02-21 2013-08-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Tim receptors as virus entry cofactors
WO2013124324A1 (en) 2012-02-21 2013-08-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Tam receptors as virus entry cofactors
WO2014077575A1 (ko) * 2012-11-13 2014-05-22 다인바이오 주식회사 덱에이 효소반응으로 조제한 항비만 및 항당뇨 효능을 갖는 한천 유래 네오아가로올리고당 복합 조성물
GB2542391A (en) * 2015-09-17 2017-03-22 Annexin Pharmaceuticals Ab Process of manufacture
GB201702144D0 (en) * 2017-02-09 2017-03-29 Annexin Pharmaceuticals Ab Therapeutic compositions
WO2019238550A1 (en) * 2018-06-12 2019-12-19 Universiteit Maastricht Method for the treatment of hypoxic-ischemic encephalopathy in newborns
CN109529017B (zh) * 2018-12-25 2022-06-14 江苏靶标生物医药研究所有限公司 一种膜联蛋白v的应用
US11357823B2 (en) * 2019-08-30 2022-06-14 Suzhou Yabao Pharmaceutical R&D Co., Ltd Method for treating cerebral stroke
US20220193192A1 (en) * 2019-08-30 2022-06-23 Suzhou Yabao Pharmaceutical R&D Co Ltd Methods of treating a traumatic brain injury
CN112057623A (zh) * 2020-06-03 2020-12-11 江苏靶标生物医药研究所有限公司 一种磷脂酰丝氨酸在制备治疗炎症性肠病药物中的应用
US20230374091A1 (en) * 2020-10-09 2023-11-23 London Health Sciences Centre Research Inc. Annexin a5 compositions and methods
CN112618696B (zh) * 2020-12-14 2023-05-05 南京大学 Annexin A5在制备治疗胆汁淤积药物中的应用
CN115245559A (zh) * 2021-04-25 2022-10-28 上海萨美细胞技术有限公司 一种用于治疗肺损伤的药物
CN117186239A (zh) * 2022-01-30 2023-12-08 南京瑞初医药有限公司 融合蛋白及其应用
CN118001375A (zh) * 2023-04-12 2024-05-10 上海萨美细胞技术有限公司 一种用于难愈性创面修复的药物
CN119097689A (zh) * 2023-06-08 2024-12-10 上海萨美细胞技术有限公司 一种用于治疗卵巢功能不全的药物
CN118001372A (zh) * 2023-07-04 2024-05-10 上海萨美细胞技术有限公司 膜联蛋白在抗衰老中的用途
CN119158000B (zh) * 2023-10-25 2025-07-18 上海萨美细胞技术有限公司 一种用于治疗肺纤维化的药物
WO2025129329A1 (en) * 2023-12-23 2025-06-26 London Health Sciences Centre Research Inc. Methods for treatment of sepsis
CN118203650B (zh) * 2024-01-26 2025-04-29 上海萨丽斐生物科技有限公司 一种用于治疗色素沉着的药物
CN118846001B (zh) * 2024-07-09 2025-09-02 上海萨丽斐生物科技有限公司 一种具有保湿、修护、紧致、抗皱功效的组合物及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0339285A3 (en) * 1988-03-31 1989-11-29 RORER INTERNATIONAL (OVERSEAS) INC. (a Delaware corporation) Recombinant endonexin ii
US5229367A (en) * 1991-01-21 1993-07-20 Sclavo S.P.A. Antiinflammatory peptide derived from human lipocortin V
NZ283171A (en) 1994-04-11 1998-02-26 Nexins Research Bv Detecting or quantifying apoptotic cells in a sample
US7645739B2 (en) * 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
US20030152513A1 (en) 2001-09-06 2003-08-14 Imetrix, Inc. Intravascular delivery of therapeutic and imaging agents to stressed and apoptotic cells using annexin V as a targeting vector
WO2003103577A2 (en) 2002-06-06 2003-12-18 Tze Chein Wun Novel recombinant anticoagulant proteins
WO2005099744A1 (en) 2004-04-15 2005-10-27 Athera Biotechnologies Ab Annexin v for preventing atherothrombois and plaque rupture
EP2173342A2 (en) 2007-06-22 2010-04-14 ETH Zurich Antivirals
MX2010001194A (es) * 2007-07-31 2010-07-30 Univ Louisiana State Conjugado de polipeptido-acido nucleico para inmunoprofilaxis o inmunoterapia para desordenes neoplasicos o infecciones.
EP2234631B1 (en) 2007-12-18 2012-09-12 Athera Biotechnologies AB Compounds and methods for the treatment of vascular disease
TR201909412T4 (tr) 2008-02-22 2019-07-22 Annexin Pharmaceuticals Ab Restenozun önlenmesi veya tedavisi için bileşikler ve yöntemler.
JP5590621B2 (ja) 2008-10-17 2014-09-17 ロンドン ヘルス サイエンシーズ センター リサーチ インコーポレイテッド 炎症性障害の処置を処置するためのアネキシンおよびその使用
MA41020A (fr) * 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome

Also Published As

Publication number Publication date
CA2740557C (en) 2020-04-14
CN102256617B (zh) 2015-04-08
EP2349321A4 (en) 2012-12-19
CN102256617A (zh) 2011-11-23
EP2349321A1 (en) 2011-08-03
JP2012505837A (ja) 2012-03-08
US20120014920A1 (en) 2012-01-19
CA2740557A1 (en) 2010-04-22
EP2349321B1 (en) 2020-04-22
WO2010043045A1 (en) 2010-04-22
US9192649B2 (en) 2015-11-24

Similar Documents

Publication Publication Date Title
JP5590621B2 (ja) 炎症性障害の処置を処置するためのアネキシンおよびその使用
KR102113809B1 (ko) 조직 재생을 유도하기 위한 펩티드 및 그의 이용
Trujillo et al. A novel mechanism for CCR4 in the regulation of macrophage activation in bleomycin-induced pulmonary fibrosis
JP7005019B2 (ja) 組織修復のための二重特異性治療用タンパク質
Schuepbach et al. Protection of vascular barrier integrity by activated protein C in murine models depends on protease-activated receptor-1
Song et al. Bone marrow-derived tenascin-C attenuates cardiac hypertrophy by controlling inflammation
JP2013541550A (ja) 低分子ペプチド阻害剤によるＣＤ４０Ｌ／Ｍａｃ−１相互作用の選択的ターゲティングならびに炎症およびアテローム形成の治療のためのその使用
JP2023511358A (ja) 線維化、肥大または心不全の処置または予防における使用のための骨髄由来増殖因子
US9006221B2 (en) Method of modulating ship activity
US20110229525A1 (en) Modulation of cytokine signaling
Wang et al. Toll-like receptor 4 signaling confers cardiac protection against ischemic injury via inducible nitric oxide synthase-and soluble guanylate cyclase-dependent mechanisms
Koren et al. The cardiac maladaptive ATF3-dependent cross-talk between cardiomyocytes and macrophages is mediated by the IFNγ-CXCL10-CXCR3 axis
CN110167564A (zh) 调节tjp1表达以调节心脏细胞的再生
US20170198011A1 (en) Composition for treating sepsis or septic shock comprising the peptide originated from the smad6
CN106063928B (zh) 一种多肽或其衍生物在治疗高血压性心肌肥厚中的应用
US20160206699A1 (en) Use of interleukin 10 mrna transfected macrophages in anti-inflammatory therapies
CN118252913B (zh) 多肽偶联物及其在射血分数保留的心衰中的应用
US10653760B2 (en) Compositions and methods for reducing organ rejection by reducing heparan sulfate in donor transplants
EP3813871A1 (en) Anc80 encoding sphingolipid-metabolizing proteins
Rainer et al. Cardiomyocyte-specific TGFβ suppression blocks neutrophil infiltration, augments multiple cytoprotective cascades, and reduces early mortality after myocardial infarction
Smolgovsky Novel Mechanisms of T Cell Dysregulation Driving Inflammation in Experimental Heart Failure With Preserved Ejection Fraction
Abdelaziz The Protective Effects of Remote Ischaemic Preconditioning on Pressure Overload-Induced Myocardial Remodelling
RU2772733C2 (ru) Hmgb1 мутанты
Chao Toll-like Receptor Signaling: A Critical Modulator of Cell Survival and Ischemic Injury in the Heart (Invited Review)
Arnold Annexin A5 Inhibits Myocardial Inflammation and Improves Cardiac Function during Endotoxemia in Mice

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121015

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121015

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140326

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140625

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140723

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140724

R150 Certificate of patent or registration of utility model

Ref document number: 5590621

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250